Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
May 29, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M.B.A., has joined the company as Chief Legal Officer.
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
May 08, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
May 01, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
January 23, 2024 08:30 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announces that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
January 10, 2024 06:00 ET
|
Alkeus Pharmaceuticals
All three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.TEASE-3 is the first clinical trial in early-stage Stargardt disease,...
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
December 21, 2023 08:00 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive...
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 03, 2023 12:00 ET
|
Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 05, 2023 06:00 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
July 14, 2021 07:00 ET
|
Alkeus Pharmaceuticals
Only drug to receive Breakthrough Therapy Designation for Stargardt DiseaseAlkeus Pharmaceuticals to discuss next steps toward filing an NDA with the FDAOngoing clinical trial of ALK-001 in dry...